Currently available screening methods have not been shown to reduce mortality in the general population, USPSTF said.
The so-called ACT sheets are one pagers that guide doctors on what to do after receiving a genetic test results for a patient.
The group that advises primary care clinicians found evidence that false-positive screening results could lead to surgical interventions in asymptomatic patients.
The guidance recommends microsatellite instability testing or immunohistochemistry be used to detect abnormalities that may lead to Lynch syndrome.
The IGRA testing market is ballooning as industrialized nations try to curb the spread of tuberculosis, but the assays still fall short in certain settings and patient populations.
The evidence-based guidelines for testing individuals at risk of latent or active TB infection include recommendations on interferon-gamma release and molecular assays.
The new guidance could benefit Hologic and Roche, both of which market molecular blood screening tests authorized by the FDA under an investigational new drug study protocol.
However, the task force stopped short of recommending the use of Cologuard or other molecular assays over a variety of well-established non-molecular testing methods.